Wegovy oral tablet: the UK's first licensed weight-loss pill explained

You've just heard about the tablet and you're wondering whether it actually works

That's a fair place to start. You can find a full breakdown of what to expect on our Wegovy tablet page, which covers everything from how the formulation works to what the titration schedule looks like. It's semaglutide (the same active ingredient as the weekly injection) reformulated as a daily pill using an absorption enhancer called SNAC, which helps the drug survive the stomach environment and enter the bloodstream. The mechanism is the same: semaglutide acts on GLP-1 receptors in the brain and gut, reducing appetite and slowing the rate at which food leaves the stomach.

The evidence for the tablet comes from the OASIS 4 phase-3 trial, which enrolled 307 adults with obesity or overweight plus at least one weight-related condition, none of whom had type 2 diabetes. After 64 weeks alongside lifestyle changes, average weight loss was around 13.6% for everyone on the tablet, rising to roughly 17% among those who followed the treatment consistently throughout. Gastrointestinal side effects were common (around 74% of tablet users reported them, compared with 42% on placebo) though most were mild to moderate and tended to ease over time. The same starting-slow titration that applies to the injection is built into the tablet schedule precisely to reduce that initial nausea.

So yes, it works. Whether it's right for you specifically depends on things a prescriber needs to assess, your weight history, other medicines you take and how well you'd manage the morning routine the tablet requires.

What the daily tablet routine actually looks like in practice

The instructions matter more here than with the injection. The tablet needs to be taken first thing in the morning on an empty stomach, with a small sip of plain water, no more than about 120ml. You then need to wait at least 30 minutes before eating anything, drinking coffee or tea, or taking any other oral medicines. Swallow it whole.

That 30-minute window is non-negotiable for absorption. It's a habit most people slot in before the kettle boils, but if your mornings are chaotic it's worth thinking through before you start. On the upside, unlike the injection pens, the tablets don't need to be kept in the fridge. Room-temperature storage makes them genuinely travel-friendly and removes one of the practical objections some people have to starting injectable treatment. If you're curious how this compares to managing the weekly pen, our guide to Wegovy in tablet form covers both formats side by side.

The titration schedule (1.5mg, 4mg, 9mg, then 25mg) is set by your prescriber. Each step takes at least a month. You don't choose the pace; your prescriber does, based on how you're tolerating the current dose. If you've been established on the 2.4mg weekly injection, it may be possible to move directly to the 25mg tablet, but that requires a fresh clinical assessment rather than an assumption.

Who the MHRA licence actually covers, and how a prescriber reads that

The Wegovy oral tablet is licensed for adults with a BMI of 30 or above, or a BMI between 27 and 29.9 alongside at least one weight-related condition such as high blood pressure, high cholesterol or prediabetes. It's used alongside a reduced-calorie diet and increased physical activity, not instead of those changes.

The licence doesn't automatically mean it's suitable for you. A prescriber weighs up your full picture: current medications, relevant conditions, whether the morning-routine requirement is realistic, and whether the tablet or the injection is a better fit for your circumstances. Oral semaglutide is absorbed differently from injected semaglutide, and some medicines can interact with the absorption window. Your prescriber will go through that with you. For a broader look at how semaglutide-based treatment works in general, the semaglutide tablets page is a useful reference.

The tablet is not available on the NHS at launch, a NICE appraisal would need to happen first, and that process takes time. For now it's a private prescription. The MHRA approval itself is confirmed by the MHRA's recent semaglutide announcements on GOV.UK; full prescribing information is available through the electronic Medicines Compendium.

How cost fits into the picture

Because this is a new product launched in summer 2026, pricing is still settling across private providers. As with the injection, any legitimate price for a prescription weight-loss medicine should include the clinical consultation, the prescription itself, and dispensing, not just the cost of the tablets. Prices that look unusually low are worth scrutinising: a breakdown of what Wegovy tablet pricing typically covers can help you make sense of the numbers you're seeing online.

A question our prescribers hear regularly is whether the tablet or the injection is cheaper in the long run, and if you're weighing up oral Wegovy against other options, that's a conversation to have during a consultation rather than a reason to delay one. Treatment through our pharmacy is reviewed personally by a GPhC-registered prescriber, with no subscription, no hidden fees, and aftercare available seven days a week. The NHS medicines page on semaglutide covers side-effect information and general patient guidance if you want to read the standard NHS summary before committing to anything.

If you'd like to find out whether the tablet is appropriate for your situation, check your eligibility through a free consultation, a prescriber will review your answers the same day.